guidanc read
guidanc suspend light upsid record
patient add rebound new patient start
suspens feel overli prudent number like move
higher delay longer expect unlik
derail momentum mse pt
anoth strong quarter deliv revenu
ahead mse street estim result reflect pt
momentum acceler sequenti declin vs strong start
year vs show sequenti declin point worth
us revenu ahead mse
reflect momentum stabil us driven stock
dynam minim like less driven
use immateri indic underli fundament strong
ex-u revenu ahead mse reflect
pt sequenti momentum acceler broad-bas
intern strength libr also strong ex-u q/q
growth vs support expans share
global saw record new patient start quarter
estim given compani ad new patient
plan doubl manufactur capac track plant
expect malaysia
gross margin lower rel inflect
expect light tradit cycl revenu product opex
remain elev third consecut quarter
trend exhibit full summari result vs mse
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
guidanc suspend necessari follow beat clear
origin guidanc midpoint move higher
factor worth explor relat suspend guidanc new patient
start advers mix/pati assist adjust model
includ impact new patient start methodolog detail
manag comment impact new start
sever indic alreadi seen improv trough
unlik start would derail previou guidanc rang relat
mix econom impact unemploy worsen year
could impact patient cgm choic financi assist program
payor polici dilig compani commentari impli like
reflect overli prudent conservat immin price risk note
cover type intens patient
estim move higher previous estim impact
new patient start revenu hit driven although
patient assist program like add compani annual price
headwind origin estim manag clear
impact new patient start mute vs model
neg start impact like trough learn dexcom
patient self-start/ self-train drive continu confid patient
adopt therapi vs pump consist
math note quarter revis estim reflect impact
new start quarter headwind also rais underli
number larger instal patient base follow net model
revenu origin
guidanc model gross margin oper margin
ep
delay driven clinic trial delay across med-tech industri
delay pivot surpris said minimum delay
seem extens enrol center disrupt light pandem could
certainli delay trial start date beyond diabet patient
underli health condit unfortun proven greater
risk complic includ higher hospit fatal rate
may drive increas precaut around enrol diabet patient
clinic trial bring patient clinic etc discuss suggest delay
tie clinic trial dynam technic issu devic
would note demand market libr delay lower
immin need clear factor
manag decis see commerci roll-out closer
vs overal delay increment competit risk posit
deriv abbott today comment well recent expert panel
see suggest expand continu lift boat
catalyst updat includ on-going type penetr geograph
expans expect receiv unitedhealthcar coverag type
intens patient like continu drive adopt type
insulin-intens patient patient cohort us
current instal base estim regard geograph
expans receiv regulatori approv australia south korea
japan manag plan launch market later year
japan launch cash-pay product late hope
real-tim cgm reimburs greater flash glucos monitor
reimburs
lrp continu look conserv pt maintain
lrp guidanc sinc decemb analyst day target
revenu clearli conserv given compani progress toward
mark year earli indic confid
abil produc cog product reach scale
view impli lrp margin guidanc
could also prove conserv model revenu
abbott libr deck competit remain import
factor cgm still meaning under-penetr
continu see room libr success
mention disrupt form factor may enabl penetr beyond insulin-
intens diabet popul analyt updat price target
base ev sale multipl premium high-growth
million except ep
sale
sale
sale
sale
price target reect ev sale multipl premium high growth devic
continu glucos monitor cgm
expos signic secular growth
expand type
type diabet us alon see
long runway cgm penetr grow
long term driven
product evolut improv form
factor integr insulin dose
accuraci eas use pharmaci
technolog leadership
sustain full launch
competit present price risk
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
materi telehealth hospital-driven
upsid beyond libr continu
prove market expans premium price
sustain libr seen inferior
product success non-intens
pbm distribut drive clear path
om
revenu growth sustain
pressur price pressur larg
off-set volum shift
pharmaci integr system
type adopt rate
lower share price pressur limit
protabl guardian libr becom
competit core medicar
user libr disrupt price model
sensor price collaps cgm fail gain
traction non-intens popul
delay unabl drive gm expans
new patient larg pharmaci
channel sustain us growth europ
sustain technolog
leadership form factor/ integr
advantag competitor
china india
view explan region hierarchi
research highest favor quintil
libr delay beyond
launch ahead expect late
price headwind less anticip
guardian libr competit greater
expect limit new patient start
limit path protabl
delay failur pipelin catalyst
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
dollar million except per share data
sg sale
 sale
